Menu
We are focused on the development of localized theranostic solutions that completely change the way bacterial infections are diagnosed and treated. Combine precision imaging with targeted interventions to improve patient outcomes.
Sabiad BV was founded as a spin-off from the University Medical Center Groningen (UMCG) to commercialize two decades of research into staphylococcal surface proteins by Prof. Jan Maarten van Dijl. We aim to transform the detection and treatment of bacterial infections with a tracer based on the 1D9 antibody, with a focus on Staphylococcus aureus (SA) infections.
“At Sabiad, we believe that infection management should be as precise and effective as possible.”
Surgical infections caused by Staphylococcus aureus (SA) are becoming harder to manage, particularly in joint replacements and fracture repairs. These infections often evade treatment, leading to prolonged hospital stays and increased healthcare costs.
Hard-to-diagnose infections often form biofilms that shield them from treatment, prolonging bacterial infection treatment and raising costs.
Our 1D9 antibody targets infections with pinpoint precision, disrupting biofilms and enabling early intervention.
Our patented StaphMark technology sets the gold standard for bacterial infection diagnosis & treatment. It accurately identifies infections in real-time, and then uses targeted therapy to tackle the infection directly, while protecting surrounding healthy tissue.
Real-time detection of bacterial infections with StaphMark solution.
Targeted treatments that focus on infections, protecting healthy tissues.
Disrupts biofilms effectively, reducing the chances of infection recurrence.
Localized therapies that reduce reliance on broad-spectrum antibiotics.
At Sabiad, we revolutionize bacterial infection treatment by combining precise diagnostics with powerful therapies. We address infections like Staphylococcus aureus at their source—quickly, effectively, and with a personalized touch.
Here’s how Sabiad supports different roles in healthcare:
Improve treatment outcomes by targeting bacterial infections with precision therapies.
Make quicker, data-driven treatment decisions with real-time diagnostic insights.
Reduce costs by preventing infections, cutting antibiotic use, and minimizing re-admissions.
Make quicker, data-driven treatment decisions with real-time diagnostic insights.
Improve treatment outcomes by targeting bacterial infections with precision therapies.
Access real-time infection data during surgery to reduce complications and improve healing.
Reduce costs by preventing infections, cutting antibiotic use, and minimizing re-admissions.
Theranostics combines diagnostic and therapeutic capabilities in a single platform, allowing for precise detection and targeted treatment of diseases like bacterial infections. It enables real-time identification of infections and immediate, tailored interventions.
By targeting infections directly and accurately, theranostic technologies reduce the need for broad-spectrum antibiotics, which helps slow down the development of antibiotic-resistant bacteria.
Early detection often relies on advanced imaging, rapid diagnostics, and blood tests. Real-time diagnostic tools, like those used in theranostics, can detect infections early, even in challenging environments like biofilms.
If left untreated, bacterial infections can spread, leading to more severe complications, such as sepsis, organ damage, or in severe cases, death. Early detection and treatment are essential for effective management.
Sabiad develops advanced solutions that focus on precision diagnostics and treatments for bacterial infections. By combining cutting-edge research with theranostic platforms, we help clinicians identify and treat infections more effectively.